ecrin-mdr-crcClinical2006AdenocarcinomaAnticoagulantsColon CancerColonic NeoplasmsAdenocarcinomaAnticoagulantsColon CancerColonic NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2037746United States12RECISTTargeted therapyCoagulation-dependentTissue factorProtein CLeucovorinRNAPc2FOLFIRIColorectal carcinoma (CRC)XELOXMetastatic colorectal carcinoma (mCRC)FOLFOX5-FU-based chemotherapyFactor VIIaECRIN MDRSuspendedfalseSafety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon CancerThis is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This trial will be performed to initiate identification of a safe and effective dose of twice-weekly, subcutaneous rNAPc2 for the second-line treatment of metastatic colorectal carcinoma in combination with contemporary 5-FU-based chemotherapy.2006-12-152037746NCT00443573